Trial Profile
Randomized, double-blind, placebo-controlled, parallel-group study of the safety and efficacy of imeglimin or placebo add-on therapy in type 2 diabetic subjects not adequately controlled by sitagliptin monotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 May 2014
Price :
$35
*
At a glance
- Drugs Imeglimin (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Poxel
- 10 Apr 2014 Results published in the Diabetes Care.
- 25 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
- 05 Nov 2012 Status changed from recruiting to completed based on a Poxel media release.